Amiza-250 Injection

Amikacin 250 mg / 2 ml Injection — Adult Aminoglycoside Antibiotic Therapy

Amiza-250 Injection — Amikacin 250 mg / 2 ml from Trumac Healthcare PCD Pharma Franchise India

Composition Amikacin 250 mg / 2 ml
Dosage Form Injection (IV/IM)
Pack Type Vial
Pack Size 1 Vial of 2 ml (250 mg)
MRP ₹ 85
Therapy Injectable + Antibiotic — Aminoglycoside Antibiotic
Storage Store below 25 °C, protected from light. Do not freeze.

📱 WhatsApp Enquiry📞 Call: +919041677932

About Amiza-250 Injection

Amiza-250 Injection contains Amikacin Sulphate 250 mg in 2 ml, the mid-strength vial commonly used for routine adult dosing of aminoglycoside therapy. Amikacin remains the workhorse aminoglycoside in Indian hospital practice due to its stability against the enzymatic resistance mechanisms that inactivate gentamicin and tobramycin.

It provides potent bactericidal activity against gram-negative pathogens including Pseudomonas aeruginosa, Klebsiella, Escherichia coli, Proteus, Serratia, Enterobacter and Acinetobacter — particularly relevant in serious nosocomial infections, neutropenic sepsis and complicated urinary or abdominal infections.

Amiza-250 is manufactured by Trumac Healthcare under WHO-GMP conditions in injectable-grade facilities. Available for monopoly-based PCD pharma franchise, government tenders and third-party manufacturing — a steady-volume hospital SKU.

Indications

  • Serious gram-negative bacterial infections — septicaemia, complicated UTI
  • Hospital-acquired pneumonia and ventilator-associated pneumonia
  • Complicated intra-abdominal infections (with beta-lactam)
  • Skin, soft tissue and post-surgical infections
  • Empirical therapy in febrile neutropenia
  • Adjunct in multi-drug-resistant tuberculosis

Mechanism of Action

Amikacin binds irreversibly to the 30S bacterial ribosomal subunit, causing mRNA misreading and inhibition of protein synthesis. The resulting non-functional proteins damage bacterial cell membranes, producing rapid bactericidal effect. Activity is concentration-dependent with a long post-antibiotic effect supporting once-daily dosing.

Dosage & Administration

Adults: 15 mg/kg/day, typically given as a single daily dose by IM injection or slow IV infusion. Dose adjustment required in renal impairment based on serum levels. Treatment duration typically 7–10 days.

Side Effects

Nephrotoxicity, ototoxicity (cochlear and vestibular), neuromuscular blockade. Local injection site pain. Less commonly: hypersensitivity, rash, transient hepatic enzyme elevation.

Contraindications & Precautions

Hypersensitivity to aminoglycosides. Concomitant nephrotoxic/ototoxic drugs without monitoring. Pre-existing 8th cranial nerve damage. Myasthenia gravis. Pregnancy (Category D). Therapeutic drug monitoring strongly advised in renal impairment.

Storage

Store below 25 °C, protected from light. Do not freeze.

PCD Pharma Franchise & Third-Party Manufacturing
Amiza-250 Injection is available for monopoly-based PCD pharma franchise across India and for third-party manufacturing under your brand. WHO-GMP certified, with full visual-aid and promotional support. Become a Trumac franchise partner →

Frequently Asked Questions

What is Amiza-250 Injection used for?

Amiza-250 Injection contains Amikacin 250 mg/2 ml and is used to treat serious gram-negative bacterial infections including septicaemia, complicated UTI, hospital-acquired pneumonia and intra-abdominal infections.

What is the difference between Amiza-100 and Amiza-250?

Both contain Amikacin but at different strengths and pack sizes. The 250 mg vial is more suited to standard adult dosing; the 100 mg vial is more commonly used in paediatric or low-weight patients.

Is Amiza-250 available for PCD pharma franchise?

Yes, Trumac Healthcare offers Amiza-250 Injection on monopoly-based PCD pharma franchise, government tenders and third-party manufacturing.

How should Amiza-250 Injection be stored?

Store below 25 °C, protected from light. Do not freeze. Use immediately after opening.

Is Amiza-250 WHO-GMP certified?

Yes, Amiza-250 Injection is manufactured in WHO-GMP and DCGI-compliant injectable facilities.

Related Products

B2B Disclaimer: This page is part of a Business-to-Business (B2B) pharmaceutical catalog intended for distributors, PCD franchise partners and healthcare professionals. Information provided is for commercial and educational reference only. Not for consumer sale. Patients must not self-medicate; please consult a qualified medical practitioner. All trade inquiries are subject to valid Drug License and GST documentation.